Search

Displaying results 2861 - 2870 of 7687 in total
  1. Target

    Immunoglobulin kappa variable 2D-28

    go.drugbank.com/bio_entities/BE0004341
    TargetHumans

    V region of the variable domain of immunoglobulin light chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocy...

    Synonyms: Ig kappa chain V-II region FR
  2. Drug

    Ixazomib

    go.drugbank.com/drugs/DB09570
    ApprovedInvestigational

    [A264329] Ixazomib was approved by the FDA on November 20, 2015, making it the first oral proteasome inhibitor approved in the US.

  3. Drug

    Pitolisant

    go.drugbank.com/drugs/DB11642
    ApprovedInvestigational

    FDA approved the use of pitolisant in 2019 for excessive daytime sleepiness (EDS) associated with narcolepsy in adults.[L8063]

  4. Drug

    CRA-028129

    go.drugbank.com/drugs/DB05951
    Experimental

    CRA-028129 is cathepsin S inhibitor which is under investigation for the treatment of psoriasis.

  5. Drug

    Ferrous glycine sulfate

    go.drugbank.com/drugs/DB14501
    Approved

  6. Drug

    Etizolam

    go.drugbank.com/drugs/DB09166
    Investigational

    It is not approved for use by FDA in the US; however it remains unscheduled in several states and is legal for research purposes. … It is an agonist at GABA-A receptors and possesses amnesic, anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant properties.

  7. Drug

    AT2220

    go.drugbank.com/drugs/DB05200
    Investigational

    GAA to the lysosome, where it can perform its normal function. … AT2220 is an experimental, oral therapy for the treatment of Pompe disease and belongs to a class of molecules known as pharmacological chaperones.

  8. Drug

    Rifalazil

    go.drugbank.com/drugs/DB04934
    Investigational

    Rifalazil is a derivative of the antibiotic rifamycin. It is being investigated by ActivBiotics for the treatment of various bacterial infections.

  9. Drug

    Affitope AD01

    go.drugbank.com/drugs/DB06086
    Investigational

    Affitope AD01 is an investigational drug developed for immunization to treat Alzheimer's Disease.

  10. Drug

    rhThrombin

    go.drugbank.com/drugs/DB04923
    ApprovedWithdrawn

    The production of recombinant proteins is not dependent on the availability of blood from animals or human donors and can be scaled-up to meet market demand. … ZymoGenetics is developing rhThrombin, a recombinant form of human thrombin that is not derived from animal or human blood, as an aid to controlling bleeding during surgery.